Published in final edited form as:

J Adolesc Health. 2018 August ; 63(2): 245–248. doi:10.1016/j.jadohealth.2018.05.011.

Identifying missed clinical opportunities in delivery of overdose prevention and naloxone prescription to adolescents using opioids

J. Deanna Wilson, MD, MPH^{a,1}, Justin Berk, MD, MPH, MBA^{a,b}, Hoover Adger, MD, MPH, MBA^a, and Leonard Feldman, MD^{a,b}

^aDepartment of Pediatrics, Division of General Pediatrics and Adolescent Medicine, Johns Hopkins University School of Medicine, 200 North Wolfe Street, Baltimore, MD 21287, Fax: 410-502-5440

^bDepartment of Internal Medicine, Division of General Internal Medicine, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, MD 21287

Abstract

Purpose: Pediatricians play a role in reducing opioid-related harms, including deaths, for patients and families. We examine knowledge, attitudes and barriers to overdose prevention and naloxone prescribing in the clinical setting by pediatric trainees.

Methods: Pediatric trainees at an academic medical center were surveyed using an adapted 17-item instrument examining knowledge, beliefs and attitudes of naloxone and overdose prevention.

Results: 82% reported frequent exposure to patients using opioids and at-risk of overdose. While 94% felt they had responsibility to educate patients about overdose risk, only 42% ever discussed overdose prevention. The majority (71%) were aware of naloxone as a prevention measure, but only 10% ever prescribed naloxone.

Conclusion: Pediatric residents frequently encountered patients using opioids, but the majority failed to deliver interventions to reduce overdose and related harms. We need concerted efforts to educate pediatric providers on delivering overdose harm prevention to opioid-using adolescents as part of routine clinical care.

Correspondence to: J. Deanna Wilson.

¹Present address: Divisions of General Internal Medicine and Adolescent and Young Adult Medicine, University of Pittsburgh School of Medicine, 200 Meyran Avenue, Suite 200, Office 213, Pittsburgh, PA 15213, wilsonjd@pitt.edu, Phone: 610-618-0932; Fax: 412-692-4825

Implications and Contribution:

Despite a crisis of opioid-related overdose and overdose deaths in adolescents and young adults, pediatricians receive inadequate training to reduce harms associated with opioid use. While they see adolescents at-risk for overdose, few delivered interventions to reduce opioid-related morbidity and mortality, such as prescribing naloxone or delivering risk reduction counseling.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of interests: There are no conflict of interests for any author and no corporate sponsors.

Keywords

Opioid-related disorders; medical education; drug overdose

Amidst the national opioid crisis, there are high rates of prescription opioid use and misuse amongst adolescent populations [1,2]. There is growing recognition that pediatricians have a critical role to play in screening for opioid use, diagnosing opioid use disorders, treating or referring patients for treatment, and reducing opioid-related harms, including deaths, for patients and their families. [3]. Despite national efforts to reduce opioid prescribing and increase delivery of overdose counseling prevention and naloxone, an opioid antagonist that can reverse overdose, there has been limited outreach to pediatric providers[4,5]. Our research examines pediatric trainees to document current naloxone prescribing practice and exposure to patients using opioids, knowledge of overdose risk and naloxone, and attitudes and barriers to overdose prevention in pediatric settings.

Methods:

Study occurred at academic medical center in Baltimore, Maryland. We surveyed residents using an adapted 17-item instrument that was content and face-validated using cognitive interviews and pilot testing [6]. We examined exposure to patients with opioid use disorders and information on beliefs and attitudes related to naloxone and overdose prevention. Individuals who had not prescribed naloxone were asked to rank barriers to naloxone prescription on a 4 point-Likert scale from 1, no problem at all, to 4, a major problem. Clinical vignettes, representing a range of ages from 12 to 21 years and diverse substances, asked the resident if the patient was at no, low, moderate or high risk of overdose and whether or not they would prescribe naloxone. The research project was deemed exempt by IRB.

Results:

Fifty-one of 69 pediatric residents (response rate of 73.9%) completed the survey. Study participants represented all three years. The majority of residents were female (78%; n=40).

Exposure to opioids and baseline beliefs

Eighty-two percent of residents reported providing care to patients who had misused opioids, and 82% reported caring for patients who they assessed as at-risk of opioid overdose. Ninety-four percent felt it was their responsibility to reduce overdose risk in their patients. 98% “somewhat agreed” or “strongly agreed” that they wanted to learn how to deliver risk reduction counseling.

Self-efficacy

There was overall low self-efficacy with over three-quarters of the residents (84%) reporting low confidence they would be able to prescribe naloxone in the future (Figure 1). Seventy-one percent of residents indicated that they were aware of naloxone as an overdose prevention measure and 89% were willing to prescribe it for outpatient use, however, only

42% had ever counseled patients on ways to prevent overdose and only 10% had ever prescribed naloxone to eligible patients. There were no differences by year of training.

Barriers to naloxone prescription

The most common barriers to naloxone prescribing among those willing to prescribe were deficits on how to prescribe naloxone (mean=3.03(1.03)) and lack of understanding eligibility criteria (m=2.78(1.07)). Residents *not* willing to prescribe naloxone (n=5) endorsed similar barriers, but they were also more concerned about factors such as side-effects of naloxone (m=2.40(0.89), whether naloxone would work or be used correctly (m=2.40(0.89), costs related to naloxone (m=2.40(0.89)), and the notion that naloxone does not treat addiction (m=2.40(0.89)) (Figure 1).

Clinical vignettes:

Despite correctly recognizing patients at elevated risk of overdose, residents were not uniformly willing to prescribe naloxone for these patients (Table 1).

Discussion:

Our study is among the first to examine naloxone and barriers to overdose prevention in a pediatric setting. The majority of pediatric residents cared for patients using opioids and at risk for opioid-related harm. We found significant unmet needs for adolescent opioid-users. Among respondents, the majority of pediatricians in our study were willing to provide overdose prevention counseling and naloxone, but they were prevented by knowledge deficits about counseling patients on reducing risk or prescribing naloxone. Similar studies of providers for adults have demonstrated the same recognized need without delivery of overdose prevention [6], suggesting trainees across all disciplines require similar support and targeted education to improve self-efficacy and delivery of overdose prevention.

Pediatricians are tasked with providing age-appropriate education and anticipatory guidance in a variety of domains [7]. As adolescents are at increased risk for opioid-related harms compared to older adults using opioids [8,9], pediatricians have a unique role to address misconceptions amongst adolescent opioid-users. Simple messages could correct misconceptions, for example, Frank et al (2015) found adolescents incorrectly believed prescription opioids and non-injection routes of administration protected them from overdose risks and had limited exposure or knowledge of naloxone [8]. Trainees may not receive adequate education to deliver harm reduction counseling to these patients as less than one in five residents counseled patients they believed to be at increased risk of opioid-related overdose about ways to minimize their overdose risk.

Surprisingly, data from clinical vignettes show that even when recognizing patients at medium or high-risk of overdose, not all residents would automatically prescribe naloxone. Although we do not know what influences these decisions, research suggests physicians in general do poor jobs about implementing risk reduction practices into primary care settings [10]. Future interventions should stress the importance of linking risk assessment to naloxone prescription for all medium- to high-risk patients.

The study is limited by its single institution nature. Baltimore city is a unique environment to explore naloxone prescribing as there has been a concerted effort from the state and local health departments to increase community awareness of naloxone [6], however, even in this setting, few providers ever prescribed naloxone or discussed overdose. At pediatric programs in other parts of the country, there is likely even less knowledge of and exposure to naloxone and prevention counseling and so we must be cautious about generalizing our findings to these settings. In addition, although we had a representative sample and a high survey response rate, non-survey participants in the study may be less aware of naloxone as a prevention strategy and less willing to prescribe it than non-participants.

In order to make progress addressing the opioid epidemic nationally, we need to engage clinicians seeing patients across the life-spectrum to not only reduce risks associated with opioid use disorder, but to also mitigate the harms associated with risky opioid misuse. Addiction is a disease with its roots in adolescence, and pediatric programs have to adequately train providers to address the growing need. As we continue to expand educational efforts related to overdose prevention, we should target providers in a range of specialties, including those devoted to the care of adolescents and young adults.

Acknowledgements:

This work was supported by the Johns Hopkins University Scholars' program. The Scholars' Fund had no role in the design, analysis, interpretation of the data, writing of manuscript, or decision to submit the article for publication. Dr. Wilson was supported through the Health Services and Research Administration's Maternal Child Health Bureau LEAH program (T71MC08054) and the National Institutes of Health (T32HD052459-07). Preliminary data was presented at the meeting for the Association for Medical Education and Research in Substance Abuse in November 2016.

References:

- [1]. McCabe SE, West BT, Veliz P, et al. Trends in Medical and Nonmedical Use of Prescription Opioids Among US Adolescents: 1976–2015. *Pediatrics*. 2017;139(4). <http://pediatrics.aappublications.org/content/139/4/e20162387>. Accessed 19 November 2017
- [2]. Curtain SC, Tejada-Vera B, Warner M. Drug Overdose Deaths among adolescents aged 15–19 in the United States: 1999–2015. NCHS Data Brief. No 282: August 2017. Accessed at <https://www.cdc.gov/nchs/data/databriefs/db282.pdf> Accessed 19 November 2017.
- [3]. Bass PF. Opioids: A pediatric epidemic. *Contemporary Pediatrics*. 2016 <http://contemporarypediatrics.modernmedicine.com/contemporary-pediatrics/news/opioids-pediatric-epidemic?page=0,0>
- [4]. Mueller SR, Walley AY, Calcaterra SL, Glanz JM, Binswanger IA. A review of opioid overdose prevention and naloxone prescribing: implications for translating community programming into clinical practice. *Subst Abus*. 2015;36(2):240–53. [PubMed: 25774771]
- [5]. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. *MMWR Morb Mortal Wkly Rep*. 2012;2;61(6):101–5. [PubMed: 22337174]
- [6]. Wilson JD, Spicyn N, Matson P, et al. Internal medicine resident knowledge, attitudes, and barriers to naloxone prescription in hospital and clinic settings. *Subst Abus*. 2016;37(3):480–487. [PubMed: 26820604]
- [7]. AAP Policy Statement. Substance use screening, brief intervention, and referral to treatment for pediatricians. *Pediatrics*. 2011;128(5):
- [8]. Frank D, Mateu-Gelabert P, Guarino H, et al. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. *Int J Drug Policy*. 2015;26(1):84–91. [PubMed: 25151334]

- [9]. Curtain SC, Tejada-Vera B, Warner M. Drug Overdose Deaths among adolescents aged 15–19 in the United States: 1999–2015. NCHS Data Brief. No 282: August 2017. Accessed at <https://www.cdc.gov/nchs/data/databriefs/db282.pdf> Accessed 19 November 2017.
- [10]. Starrels JL, Becker WC, Weiner MG, Li X, Heo M, Turner BJ. Low use of opioid risk reduction strategies in primary care even for high risk patients with chronic pain. J Gen Intern Med. 2011;9;26(9):958–64. [PubMed: 21347877]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1.

Panel A represents barriers to naloxone prescription among those who report willingness to prescribe naloxone who have not yet done so (N=40) compared to Panel B, which represents barriers to naloxone prescription among those who are not willing to prescribe naloxone (N=5). Panel C represents a treatment cascade highlighting different levels of unmet need in delivery of overdose prevention (n=50). abbreviations: OD=overdose. SUD: substance use disorders.

Table 1.

Sample clinical vignettes assessing opioid overdose risk and willingness to prescribe naloxone (N=50).

Condensed versions of clinical vignettes	Viewed as Medium or High Risk of Overdose (%) yes	Would Prescribe Naloxone (%) yes
20 year-old African-American male with history of severe motor vehicle accident 6 months prior. Presents for well child visit. Prescribed 90 mg MS Contin daily for chronic leg and back pain. Over past 3 months, has been taking more frequently. Refilling prescriptions earlier each month.	98	75
21 year-old white male with cystic fibrosis. Admitted for pneumonia. Reports prescription opioid abuse. Snorting 60 mg Oxycontin three times a day.	98	81
17 year-old white female admitted following overdose. Reports using prescription opioids after she had a fracture two years ago with escalation in use until she started injecting first Dilaudid and then heroin 3 months ago. This was her 1 st overdose and she is interested in treatment.	94	79
15 year-old African-American male with Sickle Cell Disease complicated by bilateral hip avascular necrosis. Admitted with vaso-occlusive crisis. He is on chronic opioids at home, which he reports taking as prescribed: 30 mg of MSContin two times a day with 10 to 15 mg of oxycodone for break-through pain about two to three times a day.	80	64